News

The data suggest that PrimeC's modulation of iron homeostasis may be a key mechanism in its therapeutic effect, supporting its advancement to phase 3 trials.

The medical director of the Toronto Memory Program at the University of Toronto gave clinical perspective on the promise of mivelsiran, an investigational RNA interference therapeutic, and the idea behind using RNA therapies to treat Alzheimer disease. [WATCH TIME: 5 minutes]

Researchers detected annual changes in patients with preataxic and early ataxic spinocerebellar ataxia in brain MRI imaging, clinical scores, gait parameters, and retinal thickness.

The professor of human genetics at the University of Miami discussed the significance of various genetic factors in Alzheimer risk and highlighted ongoing research, therapeutic challenges as well as the need for global collaboration. [WATCH TIME: 10 minutes]

The chief medical officer and head of Research & Development at Cognition Therapeutics discussed data from the phase 2 proof-of-concept SHINE study assessing CT1812, a small molecule oligomer antagonist, in early-stage Alzheimer disease.

Recent findings showed that treatment with satralizumab was likely associated with a reduction in the concomitant use of immunosuppressive therapies in neuromyelitis optica spectrum disorder.

The professor of human genetics at the University of Miami talked about the Alzheimer's Disease Sequencing Project which aims to provide diverse genetic data to identify therapeutic targets for Alzheimer disease. [WATCH TIME: 10 minutes]

The study highlights a dramatic decrease in income for patients following disease onset and a significantly higher proportion of them requiring social welfare jobs or disability pensions.

The chairman and chief executive officer at Biomed provided insight on the hypothesis behind a new phase 3 study assessing NA-831, an agent with neurogenesis effects, with lecanemab, a previously approved drug for Alzheimer disease. [WATCH TIME: 7 minutes]

Most relapses occurred before patients resumed immunotherapy after giving birth, suggesting that continued immunosuppression during pregnancy might help prevent attacks.

The Jerold B. Katz professor of neurology and neuroscience at Weill Cornell Medicine talked about a recent study that revealed patients who appeared unresponsive to verbal commands in vegetative or minimally conscious states retained high cognitive function. [WATCH TIME: 6 minutes]

According to a recent announcement, Larimar Therapeutics reported that all 7 sites of the open-label extension study were activated for assessing nomlabofusp in Friedreich ataxia.

The professor of neurology and Diana Davis Spencer Foundation Chair at the Jackson Laboratory discussed the emerging importance of microglia in the context of Alzheimer disease research and its potential implications for clinical trials. [WATCH TIME: 4 minutes]

A feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

Here's some of what is coming soon to NeurologyLive® this week.

The double-blind, single-dose, 5-period crossover study is expected to include approximately 40 patients with narcolepsy type 1 to test 3 dose strengths of E2086.

In a recent analysis, patients with chronic inflammatory demyelinating polyneuropathy who started their initial treatment later experienced a worsening of the disease course.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of frontotemporal dementia.

Neurology News Network. for the week ending August 17, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 16, 2024.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed new diagnostic techniques that show promise for advancing the understanding of brain pathologies like Alzheimer and Lewy Body diseases. [WATCH TIME: 3 minutes]

Acute clinical events with stable MRI were more likely among patients with multiple sclerosis who had longer disease duration, received highly effective disease-modifying therapies, and were presented with fatigue.

Prior to this, the FDA granted regenerative medicine advanced therapy designation to the cell therapy for refractory stiff-person syndrome.

The study found a 98% agreement between treating physicians’ initial diagnoses and the new MOGAD criteria.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic talked about challenges of accurately diagnosing dementia with Lewy bodies as well as new methods that show promise in guiding treatment. [WATCH TIME: 3 minutes]

Findings suggest that autoimmune diseases including neuromyelitis optica spectrum disorder and myasthenia gravis may also benefit from BCMA-CD19 bispecific CAR-T therapy.

The study suggests that overall, migraine is not directly related to traditional CVRFs, and further research is needed, especially in younger populations, to explore these relationships over longer periods.

Peter Vanderklish, PhD, chief science officer at Spingogenix, commented on a recently initiated phase 2 trial assessing investigational SPG302, a synaptic-regenerative agent in development for Alzheimer disease.

The panelists provided clinical insight on the utilization of IPX203, its potential benefits and clinical implications, as well as the practicalities of transitioning patients from other therapies.

The chair of Allegheny Health Network’s Neurosciences Institute talked about its comprehensive center that integrates multidisciplinary resources and technology to provide quality care for patients with chronic neurologic conditions. [WATCH TIME: 5 minutes]